Ashwagandha (Withania somnifera) is one of the most searched-for relaxation and sleep ingredients internationally, and brands abroad naturally ask whether a Japanese factory can make an ashwagandha product. It cannot, at least not under current Japanese rules: ashwagandha was reclassified as a substance used exclusively as a medicine in Japan over a decade ago, and that classification has not changed.

This guide explains that status, a genuine liver-safety question the wider research has raised, and which relaxation ingredients a Japanese factory can actually work with instead.

Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.

💬 Planning a relaxation-themed product made in Japan? We check the full formula against Japanese food law first, before you commit to an ingredient. See Japan-made supplement OEM.

Ashwagandha’s status in Japan

Ashwagandha was moved from Japan’s food-eligible list to its list of substances used exclusively as medicines in a 2013 revision, and it remains there, meaning a Japanese factory cannot manufacture it as a food.

Under Japan’s food-drug classification system (食薬区分), ashwagandha root had previously sat in the category of substances not automatically judged to be medicines. A February 2013 revision to the Ministry of Health, Labour and Welfare’s “Standards on the Scope of Pharmaceuticals” moved ashwagandha onto the list of substances treated exclusively as medicines, and Japanese pharmacist-association guidance describes the whole plant as prohibited from use in foods domestically as a result.

In practice, this means:

  • A Japanese GMP factory cannot manufacture an ashwagandha tablet, capsule, powder or drink as a food, at any dose or extract standardisation, because the plant itself is classified as a medicine.
  • This applies to the root as well as other plant parts. Some ashwagandha ingredient suppliers market root-only or root-extract material as gentler, but that distinction affects the traditional use profile of the material, not its current classification under Japanese food-drug rules.

A safety question worth knowing regardless of market

Independent case reports have linked ashwagandha to rare instances of liver injury, a fact that belongs in an honest picture of the ingredient even in markets where it can legally be sold as a food.

A 2023 narrative review in Pharmaceutics (PMID 37111543, doi 10.3390/pharmaceutics15041057) documented several published hepatotoxicity case reports associated with ashwagandha use, including cases involving jaundice and, in at least one case, a liver transplant, alongside a case first reported in Japan in 2004. The same review’s overall assessment was that “reports of hepatotoxic effects are so far scarce and inconclusive,” while recommending that further reports continue to be monitored. This is a safety signal from case reports, not a controlled trial establishing causation or frequency, and it is separate from — not a substitute for — Japan’s own classification of ashwagandha as a medicine.

💬 Building a relaxation-themed range and unsure which ingredients a Japanese factory can actually use? Tell us your concept and we check it against Japanese food law before you commit.

What to use instead

Japan can manufacture several other ingredients that are studied in relation to stress and sleep quality and are permitted as foods, without the regulatory block that ashwagandha carries.

Three ingredients commonly used in Japanese relaxation-themed products are permitted as foods and have their own study evidence, each covered in its own guide with honest treatment of what the evidence does and does not show:

  • GABA — appears in Japanese Foods with Function Claims for functions including easing everyday stress, though independent systematic review evidence is limited.
  • L-theanine — an amino acid from tea, studied in relation to relaxation.
  • Glycine — an amino acid studied in relation to subjective sleep quality.

None of these ingredients works the same way as ashwagandha, and none should be marketed as an ashwagandha substitute or equivalent — that would overstate the evidence and misrepresent how each ingredient is actually studied. Each has its own dose, evidence base and formulation considerations, covered in its own guide.

The check that comes first

Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product — ashwagandha fails this check outright, which is why this guide exists before you commit to a concept.

This is the same check that applies to every ingredient on this site, and ashwagandha is one of the clearest examples of an ingredient that fails it completely rather than needing a formulation adjustment. See the Japan-made supplement OEM page for how we check a full formula before quoting.

Before you ask about a relaxation-themed product

Tell us the relaxation-related benefit you want to build around, and we confirm which ingredients a Japanese factory can actually use before any formulation work begins.

  • The relaxation-related outcome you want the product associated with
  • Any ingredients you already have in mind, so we can check their Japanese status first
  • Dosage form preference
  • Countries you will sell in, and each market’s rules on ashwagandha and its labelling
  • First order and annual volume

💬 Have a relaxation-themed concept in mind? Send it to us and we will tell you plainly which ingredients Japan can make, before any formulation work begins.

Frequently asked questions

1. Can a Japanese factory make an ashwagandha product using only the root extract?
No. Japanese pharmacist-association guidance describes the whole plant, which in practice includes root and root extract, as falling under the exclusively-medicinal classification since the 2013 revision. The plant part does not change that classification under current Japanese rules.

2. Is ashwagandha’s liver-safety question specific to Japan’s decision?
No, they are separate matters. Japan’s classification is a food-drug regulatory decision from 2013, unrelated to the later case reports. The liver-safety case reports are a separate, more recent line of evidence relevant to how ashwagandha is discussed in any market, including ones where it remains a legal food ingredient.

3. Is this likely to change soon?
No confirmed move to reclassify ashwagandha off Japan’s exclusively-medicinal list was found in the sources checked for this guide. Brands should plan around the current classification rather than an anticipated change.

4. Are GABA, theanine and glycine equivalent to ashwagandha?
No. Each works differently and has its own separate evidence base. They are alternatives that Japan can legally manufacture as foods, not substitutes with matching effects.

5. Can I still sell an ashwagandha product in other markets while sourcing other ingredients from Japan?
That depends on each market’s own rules, which this guide does not cover. What this guide confirms is that a Japanese factory cannot manufacture an ashwagandha product as a food, regardless of where you plan to sell it.

Sources: 日経メディカル, “アシュワガンダが食薬区分の「薬」に” (ashwagandha reclassified under 食薬区分’s “drug” category), February 2013, describing the Ministry of Health, Labour and Welfare’s revision of the Standards on the Scope of Pharmaceuticals; 公益社団法人福岡県薬剤師会 Q&A, “アシュワガンダとは？使用する場合に気をつけることはあるか？”, describing ashwagandha as classified as “専ら医薬品” (exclusively medicinal) under Japan’s food-drug distinction and prohibited from use in foods in Japan; “Ashwagandha (Withania somnifera)-Current Research on the Health-Promoting Activities: A Narrative Review”, Pharmaceutics 2023, PMID 37111543, doi 10.3390/pharmaceutics15041057. Checked on 25 September 2026.